The Urticaria Control Test and Urticaria Activity Score correlate with quality of life in adult Japanese patients with chronic spontaneous urticaria

Background: Patients with chronic spontaneous urticaria often exhibit psychiatric comorbidities including depression that contribute to the impairment of their quality of life. How CSU and depression are linked isn't well-understood. Substance P has been shown to be increased in patients with CSU and is held to contribute to the pathogenesis of depression.Methods: We measured disease activity in 30 CSU patients without depression and 30 CSU patients with depression by using the urticaria activity score. The severity of depression was assessed with the Beck Depression Inventory. We measured SP levels in these patients as well as in 30 healthy control subjects. In patients with comorbid depression, we correlated SP levels with CSU disease activity and the severity of depression.Results: In CSU patients, disease activity and the severity of depression were positively linked. UAS7 values were higher in CSU patients with comorbid depression as compared to those without (p < 0.05). SP levels were higher in CSU patients with depression than in those without (p < 0.001), but was similar in all CSU patients compared to healthy controls. SP levels weren't correlated with UAS7 values in CSU patients with depression, whereas they were weakly but significantly correlated with BDI scores (p < 0.05).Conclusion: Our results suggest that, in CSU patients with comorbid depression, CSU disease activity affects the severity of depression. CSU patients with high disease activity should be explored for comorbid depression.

Download Full-text

The Arabic Urticaria Activity Score and Chronic Urticaria Quality of Life Questionnaire: validation and correlations

International Journal of Dermatology ◽

10.1111/ijd.15006 ◽

2020 ◽

Vol 59 (8) ◽

pp. 893-901

Author(s):

Samah Tawil ◽

Carla Irani ◽

Riwa Kfoury ◽

Pascale Salameh ◽

Ilaria Baiardini ◽

...

Keyword(s):

Quality Of Life ◽

Chronic Urticaria ◽

Activity Score ◽

Life Questionnaire ◽

Questionnaire Validation ◽

Quality Of Life Questionnaire ◽

Urticaria Activity Score

Download Full-text

Comparative assessment of quality of life in chronic spontaneous urticaria receiving second generation anti histamines: A real world study

10.25259/ijsa_2_2021 ◽

2022 ◽

Vol 1 ◽

pp. 7-10

Author(s):

Bela Shah ◽

Ankita Choudhary ◽

Neha Jangid ◽

Deval Mistry ◽

Shikha Shah ◽

...

Keyword(s):

Quality Of Life ◽

Real World ◽

Detrimental Effect ◽

Standard Dose ◽

Comparative Assessment ◽

Chronic Spontaneous Urticaria ◽

First Choice ◽

The Difference ◽

Urticaria Activity Score

Objectives: Chronic spontaneous urticaria (CSU) is correlated with a high detrimental effect on the quality of life (QoL). Antihistamines are the first choice drugs in the management of CSU. QoL is important in the evaluation of the efficacy of antihistamines, as these are the most commonly used in CSU. Materials and Methods: In this comparative, three-arm study, patients with CSU were randomized to standard dose of either bilastine, fexofenadine, or levocetirizine for a period of 4 weeks. Patients were assessed for improvement in their QoL based on chronic urticaria QoL questionnaire (CU-Q2oL) questionnaire and urticaria activity score (UAS). Results: Fifty-eight CSU patients were randomized to bilastine (n = 23), fexofenadine (n = 18) and levocetrizine (n = 17) groups. There was significant improvement in CU-Q2oL and UAS score in all the groups during study period. 83%, 72%, and 65% patients reported improvement in CU-Q2oL score in bilastine, fexofenadine, and levocetrizine group, respectively. Bilastine was associated with significant improvement in CU-Q2oL compared to fexofenadine and levocetrizine (P < 0.05). Mean reduction in UAS score was 86%, 77%, and 68% in bilastine, fexofenadine and levocetrizine group respectively. The difference was statistically insignificant between the groups. The CU-Q2oL total score correlated more strongly (r = 0.62; P = 0.001) with the UAS7 in bilastine group than fexofenadine (r = 0.57; P = 0.01) and levocetrizine groups (r = 0.53; P = 0.02). Conclusion: The results of the study proved that, in CSU patients, QoL was improved significantly with bilastine as compared to fexofenadine and levocetirizine.

Download Full-text

Chronisch-spontane Urtikaria: Viel hilft manchmal eben doch viel

Karger Kompass Dermatologie ◽

10.1159/000502431 ◽

2019 ◽

pp. 193-194

Author(s):

Wiebke Sondermann

Keyword(s):

Retrospective Analysis ◽

Baseline Data ◽

Chronic Spontaneous Urticaria ◽

Recommended Dose ◽

Activity Score ◽

Control Test ◽

Stepwise Approach ◽

Patient Will ◽

Urticaria Activity Score ◽

Higher Doses

The recommended dose of omalizumab for the treatment of chronic spontaneous urticaria (CSU) is 300 mg every 4 weeks, but there is no recommendation for patients who do not benefit from this dose. Our aim is to present the experiences on the use of doses of omalizumab higher than those recommended for CSU patients and to propose a protocol for updosing. This was a retrospective analysis of patients treated with omalizumab for CSU from 2 urticaria centers in Istanbul and Barcelona. The weekly urticaria activity score and/or the Urticaria Control Test (UCT) were used to monitor response. In Barcelona, a stepwise updosing regimen was preferred (450 mg first, then increasing to 600 mg), while in Istanbul, direct updosing to 600 mg was chosen. In Istanbul, 81 (88%) patients were treated with 300 mg, while 11 (12%) received 600 mg of omalizumab. In Barcelona, 7 (8.8%), 45 (56.3%), 17 (21.3%), and 11 (13.8%) patients received 150, 300, 450, and 600 mg of omalizumab, respectively. Urticaria control was achieved in 82.6% of the patients with 300 mg and in 8.7% of the patients with 600 mg in Istanbul, while it was achieved with 150 mg in 10%, with 300 mg in 48.8%, with 450 mg in 16.3%, and with 600 mg in 6.3% of the patients in Barcelona. In total, 123 (71.5%) patients responded to 150-300 mg and 26 (15.1%) to 450-600 mg. When responders to 150-300 mg (n = 123) were compared with responders to 450-600 mg (n = 26), BMI was found to be higher, and pre-omalizumab UCT was found to be lower in patients receiving updosed omalizumab (p = 0.029). Baseline data of the patients, especially BMI and pre-oma UCT, might be useful to determine if the patient will require higher doses of omalizumab. We recommend a stepwise approach starting from 450 mg and then updosing to 600 mg in CSU patients who do not respond or partially respond to 300 mg of omalizumab after 3-6 months of treatment.

Download Full-text

Evaluation of omalizumab at certain time intervals in patients with chronic spontaneous idiopathic urticaria

International Journal of Scientific Reports ◽

10.18203/issn.2454-2156.intjscirep20195299 ◽

2019 ◽

Vol 5 (12) ◽

pp. 351

Author(s):

Ömer Kutlu ◽

Engin Karaarslan ◽

Nermin Karaosmanoğlu ◽

Hatice Meral Ekşioğlu

Keyword(s):

Quality Of Life ◽

Visual Analog Scale ◽

Statistical Significance ◽

Activity Score ◽

Life Questionnaire ◽

Post Injection ◽

Analog Scale ◽

Time Intervals ◽

Urticaria Activity Score

Background: In this study, we aimed to evaluate the response of patient treated with omalizumab at certain time intervals through 6 months with pruritus visual analog scale, urticaria activity score and quality of life indexes.Methods: The study was performed on ten patients diagnosed with chronic idiopathic spontaneous urticaria. The disease was assessed by the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) and Dermatology Life Quality Index (DLQI) for every 2 weeks while was assessed by Urticaria Activity Score (UAS-7) and Pruritus Visual Analog Scale (PVAS) for once a week during the 6-month treatment period. Statistical significance was evaluated using the Mann-Whitney U test in SPSS 20. Results: Pre-treatment values of the DLQI, CU-Q2oL, UAS-7, and PVAS was statistically higher than post-treatment values of these indexes (p<0.05). The mean DLQI/ CU-Q2oL value of the patients before treatment was 17±6.09/ 52.87±22.07 while it was 19.4±16.36 at the end of 2nd-week post-injection per month, and was 21.85±16.56 at the end of 4nd-week post-injection per month during 6-months following. Statistically, PVAS score at the fourth week was higher than 2nd and 4th week (p<0.042, p<0.007).Conclusions: In this study, it was detected that omalizumab had a significant effect on DLQI, CU-Q2oL, UAS-7, PVAS scores in CISU. It can be concluded that significant increase of PVAS score at 4th week compared to scores at 2nd and 3rd week may necessitate the use of omalizumab combined with antihistamines at 4th week of the treatment.

Download Full-text

554 Chronic Urticaria Quality of Life Questionnaire (Cu-Q2 Ol) and Urticaria Activity Score (Uas)

World Allergy Organization Journal ◽

10.1097/01.wox.0000411669.38129.c9 ◽

2012 ◽

Vol 5 ◽

pp. S176

Author(s):

Nadia Aguilar ◽

Nora Hilda Segura Mendez ◽

Saul Lugo-Reyes

Keyword(s):

Quality Of Life ◽

Chronic Urticaria ◽

Activity Score ◽

Life Questionnaire ◽

Quality Of Life Questionnaire ◽

Urticaria Activity Score

Download Full-text

Interleukin 17 Receptor a Haplotype Analysis in Chronic Spontaneous Urticaria

10.21203/rs.3.rs-36841/v1 ◽

2020 ◽

Author(s):

Hesham Nada ◽

Ranya Hassan ◽

Rasha Abd El-Hamed Ibrahim ◽

Omnia Emad Abdelsalam ◽

Amal Fathy ◽

...

Keyword(s):

Quality Of Life ◽

Haplotype Analysis ◽

Complex Trait ◽

Chronic Spontaneous Urticaria ◽

Autologous Serum ◽

Interleukin 17 ◽

Allelic Discrimination ◽

Autologous Serum Skin Test ◽

Urticaria Activity Score

Abstract Background: Chronic spontaneous urticaria (CSU) is a distressing skin disease. Family clustering and heterogeneity in the onset and progression indicate that susceptibility to CSU is a complex trait. In this study, we performed haplotype analysis for one of the key player gene, IL17RA, for CSU to test the association with disease susceptibility and severity.MethodsThe study included 70 CSU patients and 30 healthy controls. The severity of the disease was evaluated by autologous serum skin test (ASST) and urticaria activity score (UAS). ASST test was done and quality of life was assessed using a questionnaire. Allelic discrimination analysis for rs4819554 and rs879577 was performed using Real-Time Polymerase Chain Reaction technology.Results: Carriers of rs4819554*G were more prone to develop CSU than its counterpart (p = 0.039), while rs4819554*A allele displayed more severe phenotype in the form of more prolonged disease duration (p = 0.040), concurrent angioedema (p < 0.001), higher level of treatment (p < 0.001), and higher score of quality of life (p < 0.001). Additionally, homozygote patients with rs879577*CC were associated with angioedema (p < 0.001). Haplotype analysis revealed that cohorts with both rs4819554*A and rs879577*T conferred protection against developing CSU (OR = 0.07, 95%CI = 0.01 - 0.32, p = 0.001).Conclusions: Our results showed that IL17RA gene polymorphisms might contribute to the increased susceptibility to CSU.

Download Full-text